One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis-Reference-Cited by-同舟云学术

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

Published:2015-02-18 Issue:5 Volume:12 Page:484-493
ISSN:1541-2555
Container-title:COPD: Journal of Chronic Obstructive Pulmonary Disease
language:en
Short-container-title:COPD: Journal of Chronic Obstructive Pulmonary Disease

Author:

McGarvey Lorcan,Niewoehner Dennis,Magder Sheldon,Sachs Paul,Tetzlaff Kay,Hamilton Alan,Korducki Lawrence,Bothner Ulrich,Vogelmeier Claus,Koch Andrea,Ferguson Gary T.

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/15412555.2014.991864

Reference26 articles.

1. Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models

2. Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol

3. 24-hour Bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists;Pharmacoepidemiology and Drug Safety;2022-05-13

2. Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies;npj Primary Care Respiratory Medicine;2020-12

3. Recent Advances in β2-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure;Journal of Medicinal Chemistry;2020-11-19

A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD

;International Journal of Chronic Obstructive Pulmonary Disease;2020-08

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD

;International Journal of Chronic Obstructive Pulmonary Disease;2020-08